Latest Breaking News On - Matt pera - Page 6 : comparemela.com

Eyebiotech Limited: EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema

Eyebiotech Limited: EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMark barakatDavid guyerJonathan prennerTony adamisMatt peraJ edward ysasagaVentures fundSv health investorsEyebiotech limited eyebioEyebio eyebiotechMerck co incAnti permeability mechanismAge related ocular neovascularization evaluationChief scientific officer

EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret™ in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema

LONDON & NEW YORK (BUSINESS WIRE) Jun 14, 2023

United statesCity ofUnited kingdomJ edward ysasagaJonathan prennerDavid guyerMatt peraMark barakatTony adamisVentures fundMerck co incSv health investorsEyebio eyebiotechEyebiotech limited eyebioAnti permeability mechanismAge related ocular neovascularization evaluation

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesStefan rileyYves sabbaghDouglasa trecoInozyme pharmaMatt peraKurt gunterExchange commissionEuropean medicines agencyDevelopment rd expensesInozyme pharma incEuropean congressEuropean calcified tissue societyCorporate communicationsPediatric investigational planFinancial guidance

Inozyme Pharma Reports Inducement Grants Under Nasdaq

BOSTON, May 03, 2023 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel.

United statesInozyme pharmaMatt peraStefan rileyInozyme pharma incCorporate communicationsStock incentive planNasdaq listing ruleNasdaq inzyNozyme pharma inc

Eyebiotech Limited: EyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team

Additions to EyeBio's leadership team include world-class disruptors with deep experience addressing urgent unmet needs in treatment of eye diseases - EyeBio co-founder Anthony P. Adamis, M.D., appointed

United statesUnited kingdomDennis riedlSarah milsomMatt peraFrances bettsIveric bioPaul stephensAnthonyp adamisDavid guyerMike daviesTony adamisAndreas wallnoeferJonathan prennerKate binghamSrinivas akkaraju